Home
|
Learning Center
|
中文版
Publications
站内成果搜索:
搜索
Alemtuzumab induction therapy in kidney transplantation
Alemtuzumab as Remission Induction Therapy in Behcet Disease: A 20-year Experience
Alemtuzumab-Based Induction Treatment Versus Basiliximab-Based Induction Treatment in Kidney Transplantation (The 3C Study): A Randomized Trial
Alemtuzumab (Campath-1H) experience in kidney transplantation what we have learned; current practices; and scope for the future?
Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use
Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA
Alemtuzumab treatment for hemophagocytic lymphohistiocytosis
Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy
Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis
Alemtuzumab: the future of chronic inflammatory demyelinating polyradiculoneuropathy treatment?
Alemtuzumab Induction Prior to Cardiac Transplantation with Lower Intensity Maintenance Immunosuppression: One-Year Outcomes
Alemtuzumab and multiple sclerosis: therapeutic application
Alemtuzumab in solid organ transplantation and in composite tissue allotransplantation
Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis
Alemtuzumab for Multiple Sclerosis
Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort
Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Grappo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial
Alemtuzumab for treatment of lymphoproliferative disorders
Alemtuzumab for giant cell hepatitis with autoimmune hemolytic anemia
Alemtuzumab: a further option for treatment of multiple sclerosis
Alemtuzumab for B-cell chronic lymphocytic leukemia
Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial
Alemtuzumab for patients with chronic lymphocytic leukaemia
Alemtuzumab by Continuous Intravenous Infusion Followed by Subcutaneous Injection Plus Rituximab in the Treatment of Patients With Chronic Lymphocytic Leukemia Recurrence
Alemtuzumab induction and recurrence of glomerular disease after kidney transplantation
Alemtuzumab vs. Interferon beta-1a in early multiple sclerosis
Alemtuzumab induction in simultaneous pancreas and kidney transplantation
Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia
Alemtuzumab with Rapid Steroid Taper in Simultaneous Kidney and Pancreas Transplantation: Comparison to Induction with Antithymocyte Globulin
Alemtuzumab Induction in Deceased Donor Kidney Transplantation
Alemtuzumab (Campath-1H)-Induced Coagulopathy in Renal Transplantation
Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation
Alemtuzumab Induction Therapy in Kidney Transplantation: A Systematic Review and Meta-Analysis
Alemtuzumab: right drug, right dose?
Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route
Alemtuzumab Use In Relapsed and Refractory Chronic Lymphocytic Leukemia
Alemtuzumab in allogeneic hematopoetic stem cell transplantation
Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial
Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Alemtuzumab for multiple sclerosis: who and when to treat?
Alemtuzumab for relapsing-remitting multiple sclerosis. Results of two randomized controlled phase III studies
Alemtuzumab as graft-versus- host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation
Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts
Alemtuzumab induction therapy in HIV-positive renal transplant recipients
Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial
Alemtuzumab based reduced intensity transplantation for pediatric severe aplastic anemia
Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients A systematic review and meta-analysis of randomized controlled trials
Alemtuzumab CARE-MS II 5-year follow-up Efficacy and safety findings
Alemtuzumab CARE-MS I 5-year follow-up Durable efficacy in the absence of continuous MS therapy
Alemtuzumab dose adjusted for body weight is associated with earlier lymphocyte repletion and less infective episodes in the first year post renal transplantation - a retrospective study
Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis
Alemtuzumab-induced remission of multiple sclerosis-associated uveitis
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
Alemtuzumab for cytolytic induction of immunosuppression in heart transplant recipients
Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 Clinical Trial
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Alembic: Automatic Locality Extraction via Migration
Alemtuzumab and Sirolimus in Renal Transplantation: Six-Year Results of a Single-Arm Prospective Pilot Study
Alemtuzumab for the prevention and treatment of graft-versus-host disease
Alemtuzumab in Multiple Sclerosis
Alemtuzumab in Kidney-Transplant Recipients
Alemtuzumab-Based Reduced-Intensity Conditioning Allogeneic Transplantation for Myeloma and Plasma Cell Leukemia - A Single-Institution Experience
Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes
Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis
Alemtuzumab and Multiple Sclerosis Another Note of Caution
Alemtuzumab in T-cell large granular lymphocyte leukaemia
Alemtuzumab Induction in Renal Transplantation
Alemtuzumab in Kidney-Transplant Recipients REPLY
Alemtuzumab Preconditioning Allows Steroid-calcineurin Inhibitor-free Regimen in Live-donor Kidney Transplant
Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations
Alemtuzumab treatment for Sezary syndrome: A single-center experience
Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
Alemtuzumab induction with tacrolimus monotherapy in 25 pediatric renal transplant recipients
Alemtuzumab and Myelodysplasia: A Story of Love and Hate (Possible Alemtuzumab-Induced Myelodysplastic Changes)
Alemtuzumab and multiple sclerosis Is it safe?
Alemtuzumab depletion failure can occur in multiple sclerosis
Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features
Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study
Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis
Alemtuzumab induction therapy in kidney transplantation – Authors' reply